MEIRAGTX HOLDINGS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.995 USD | -0.30% |
|
-10.97% | -29.49% |
Presenter SpeechAlec Stranahan (Analysts)Hey, everyone, good morning. Welcome to day 1 of the ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.01
USD
Average target price
21.6
USD
Spread / Average Target
+331.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.49% | 322M | |
| -3.54% | 102B | |
| +1.80% | 96.07B | |
| -1.80% | 21.66B | |
| -17.54% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -27.65% | 13.79B | |
| -0.83% | 13.33B | |
| +19.28% | 10.94B |
- Stock Market
- Equities
- MGTX Stock
- News MeiraGTx Holdings plc
- Transcript : MeiraGTx Holdings plc Presents at Bank of America 2022 Healthcare Conference, May-10-2022 10
